BriaCell to Present at the 3rd Annual Biologics World Nordic 2020

BERKELEY, Calif., and VANCOUVER, British Columbia, September 15, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that Dr. Bill Williams, BriaCell’s President & CEO, will be presenting at the 3rd Annual Biologics World Nordic 2020 Conference, a virtual …

BriaCell Awarded Research Grant from Wiseman Cancer Research Foundation

BERKELEY, Calif., and VANCOUVER, British Columbia, September 4, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is announcing that it has received a research grant from the Wiseman Cancer Research Foundation, a 501c(3) nonprofit organization based in Beverly Hills, CA. …

BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance

BERKELEY, Calif., and VANCOUVER, British Columbia, August 17, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that further to its news release dated August 11, 2020, it has received the approval of the TSX Venture Exchange for the shares …

BriaCell Presents Clinical and Scientific Findings at the Annual Symposium of Society of Surgical Oncology 2020

Preliminary safety and efficacy data are being presented today from the clinical trials of Bria-IMT™ in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, in combination with pembrolizumab (KEYTRUDA®; manufactured by …

BriaCell Therapeutics Corp. Announces Shares for Debt Issuance

BERKELEY, Calif., and VANCOUVER, British Columbia, August 11, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has entered into a debt settlement agreement (“Debt Settlement”) with a creditor, that has provided legal services to the Company, to …

BriaCell Files Provisional Patent Application for Novel Treatment and Diagnosis of Coronavirus Disease

BERKELEY, Calif., and VANCOUVER, British Columbia, June 24, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining compositions and methods of developing novel …

BriaCell Announces Presentation of Clinical and Scientific Findings at AACR Annual Meeting

Preliminary safety and efficacy data is being presented today from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint (PD-1) inhibitors in advanced breast cancer patients. • Clinical responses and disease control—without serious side effects—in heavily pre-treated patients with metastatic breast cancer seen with lead candidate, Bria-IMT™, with or without a PD-1 …

BriaCell CEO to Present at 3rd Annual Next-Gen Immuno-Oncology Congress in June

BERKELEY, Calif., and VANCOUVER, British Columbia, June 9, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Dr. Bill Williams, BriaCell’s President & CEO, has been invited to present at 3rd Annual Next-Gen Immuno-Oncology Congress, a …

BriaCell Presents Clinical Findings at 2020 American Society of Clinical Oncology (ASCO) Meeting

Preliminary safety and efficacy data is being presented on May 29 at 9:00 a.m. ET from the clinical trials of Bria-IMT™ alone or in combination with immune checkpoint inhibitors in advanced breast cancer: • Lead candidate, Bria-IMT™, with or without a PD-1 inhibitor, showed no serious side effects and resulted in clinical responses in heavily …

BriaCell Files Patent Application for Novel Immune Therapies for Multiple Disease Indications

BERKELEY, Calif., and VANCOUVER, British Columbia, May 20, 2020 — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, announces that it has filed a provisional patent application with the U.S. Patent and Trademark Office (USPTO) outlining a novel vaccine platform to selectively …